Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $1.03 billion. The enterprise value is $1.21 billion.
| Market Cap | 1.03B |
| Enterprise Value | 1.21B |
Important Dates
The next confirmed earnings date is Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 40.49 million shares outstanding. The number of shares has decreased by -2.60% in one year.
| Current Share Class | 40.49M |
| Shares Outstanding | 40.49M |
| Shares Change (YoY) | -2.60% |
| Shares Change (QoQ) | -3.32% |
| Owned by Insiders (%) | 2.24% |
| Owned by Institutions (%) | 115.36% |
| Float | 37.53M |
Valuation Ratios
The trailing PE ratio is 160.99 and the forward PE ratio is 9.66.
| PE Ratio | 160.99 |
| Forward PE | 9.66 |
| PS Ratio | 1.42 |
| Forward PS | 1.33 |
| PB Ratio | 1.51 |
| P/TBV Ratio | 3.38 |
| P/FCF Ratio | 7.53 |
| P/OCF Ratio | 6.77 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.73, with an EV/FCF ratio of 8.85.
| EV / Earnings | 171.94 |
| EV / Sales | 1.66 |
| EV / EBITDA | 9.73 |
| EV / EBIT | 36.32 |
| EV / FCF | 8.85 |
Financial Position
The company has a current ratio of 4.54, with a Debt / Equity ratio of 0.60.
| Current Ratio | 4.54 |
| Quick Ratio | 3.01 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 3.00 |
| Debt / FCF | 3.06 |
| Interest Coverage | 1.91 |
Financial Efficiency
Return on equity (ROE) is 0.96% and return on invested capital (ROIC) is 1.56%.
| Return on Equity (ROE) | 0.96% |
| Return on Assets (ROA) | 1.48% |
| Return on Invested Capital (ROIC) | 1.56% |
| Return on Capital Employed (ROCE) | 2.91% |
| Weighted Average Cost of Capital (WACC) | 4.29% |
| Revenue Per Employee | $876,250 |
| Profits Per Employee | $8,485 |
| Employee Count | 829 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.08 |
Taxes
In the past 12 months, PCRX has paid $9.84 million in taxes.
| Income Tax | 9.84M |
| Effective Tax Rate | 58.31% |
Stock Price Statistics
The stock price has decreased by -1.21% in the last 52 weeks. The beta is 0.20, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -1.21% |
| 50-Day Moving Average | 23.22 |
| 200-Day Moving Average | 23.60 |
| Relative Strength Index (RSI) | 62.68 |
| Average Volume (20 Days) | 493,167 |
Short Selling Information
The latest short interest is 7.39 million, so 18.25% of the outstanding shares have been sold short.
| Short Interest | 7.39M |
| Short Previous Month | 8.06M |
| Short % of Shares Out | 18.25% |
| Short % of Float | 19.69% |
| Short Ratio (days to cover) | 11.24 |
Income Statement
In the last 12 months, PCRX had revenue of $726.41 million and earned $7.03 million in profits. Earnings per share was $0.16.
| Revenue | 726.41M |
| Gross Profit | 576.66M |
| Operating Income | 33.30M |
| Pretax Income | 16.87M |
| Net Income | 7.03M |
| EBITDA | 124.33M |
| EBIT | 33.30M |
| Earnings Per Share (EPS) | $0.16 |
Balance Sheet
The company has $238.42 million in cash and $418.20 million in debt, giving a net cash position of -$179.78 million or -$4.44 per share.
| Cash & Cash Equivalents | 238.42M |
| Total Debt | 418.20M |
| Net Cash | -179.78M |
| Net Cash Per Share | -$4.44 |
| Equity (Book Value) | 693.11M |
| Book Value Per Share | 16.86 |
| Working Capital | 427.38M |
Cash Flow
In the last 12 months, operating cash flow was $151.99 million and capital expenditures -$15.33 million, giving a free cash flow of $136.66 million.
| Operating Cash Flow | 151.99M |
| Capital Expenditures | -15.33M |
| Depreciation & Amortization | 91.02M |
| Net Borrowing | -216.80M |
| Free Cash Flow | 136.66M |
| FCF Per Share | $3.38 |
Margins
Gross margin is 79.39%, with operating and profit margins of 4.58% and 0.97%.
| Gross Margin | 79.39% |
| Operating Margin | 4.58% |
| Pretax Margin | 2.32% |
| Profit Margin | 0.97% |
| EBITDA Margin | 17.12% |
| EBIT Margin | 4.58% |
| FCF Margin | 18.81% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.60% |
| Shareholder Yield | 2.60% |
| Earnings Yield | 0.68% |
| FCF Yield | 13.27% |
Analyst Forecast
The average price target for PCRX is $30.25, which is 19.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.25 |
| Price Target Difference | 19.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 0.37% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 2.01 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.01 |
| Piotroski F-Score | 8 |